导航

| 统计阶段 | 收益率 | 同类排名 |
|---|---|---|
| 今年以来 | -2.26% | 2883/4773 |
| 近一周 | -2.06% | 1145/5462 |
| 近一月 | -4.04% | 2163/5421 |
| 近一季 | -7.76% | 2525/5209 |
| 近半年 | -4.09% | 2418/4920 |
| 近一年 | -0.39% | 2720/4366 |
| 近两年 | 46.12% | 1602/2954 |
| 近三年 | 25.92% | 1238/2253 |
| 成立以来 | 62.89% | - |
| 年份 | 年收益 | 1季度 | 2季度 | 3季度 | 4季度 |
| 2026 | - - |
-3.42% 3197/4961 |
12.31% 2194/5312 |
- - |
- - |
| 2025 | 20.30% 2131/4813 |
-0.80% 2414/3635 |
1.82% 2113/4076 |
19.01% 2207/4524 |
0.08% 2238/4813 |
| 2024 | 14.76% 1011/3463 |
2.36% 792/2808 |
-1.75% 1103/3014 |
16.21% 1506/3129 |
-1.81% 1839/3463 |
| 2023 | -10.32% 1286/2656 |
3.88% 1101/2280 |
-5.13% 1380/2385 |
-2.91% 786/2515 |
-6.27% 1699/2655 |
| 2022 | -18.35% 696/2207 |
-14.29% 930/1919 |
6.93% 572/2016 |
-12.63% 746/2113 |
1.97% 1075/2208 |
| 2021 | 7.43% 497/1822 |
-2.55% 666/1255 |
9.96% 506/1330 |
-1.97% 552/1466 |
2.26% 645/1822 |
| 2020 | 40.67% 306/1250 |
-7.24% 533/1028 |
15.59% 483/1067 |
14.19% 294/1164 |
14.90% 242/1184 |
| 2019 | - - |
- - |
-2.96% 369/804 |
1.15% 427/850 |
7.39% 440/918 |
| 2018 | - - |
- - |
- - |
- - |
- - |
| 2017 | - - |
- - |
- - |
- - |
- - |
| 2016 | - - |
- - |
- - |
- - |
- - |
| 2015 | - - |
- - |
- - |
- - |
- - |
| 2014 | - - |
- - |
- - |
- - |
- - |
| 2013 | - - |
- - |
- - |
- - |
- - |
| 2012 | - - |
- - |
- - |
- - |
- - |
| 基金名称 | 最新净值 | 季增长率 |
| 万家中证港股通创新药ETF | 1.5896 | 28.31% |
| 景顺长城中证港股通创新药ETF | 1.6507 | 28.23% |
| 港股医疗 | 0.9366 | 28.18% |
| 港股医疗ETF | 1.4282 | 28.15% |
| 港股通医疗ETF工银 | 0.9464 | 28.06% |
| 港股通医疗ETF华宝 | 0.9577 | 27.97% |
| 天弘恒生沪深港创新药精选50ETF发起联接C | 1.2844 | 27.92% |
| 天弘恒生沪深港创新药精选50ETF | 0.8437 | 27.35% |
| 万家中证港股通创新药ETF发起式联接A | 1.3863 | 27.32% |
| 万家中证港股通创新药ETF发起式联接C | 1.3856 | 27.27% |
| 银华MSCI中国A股ETF VS. 长安沪深300非周期A(740101) |